Physician profile
Mitchell Z Berger
NPI 1750321956
$2,143.04
in general payments reported to CMS, 2019-2025
36 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2022: $1,227 · 2023: $485 · 2024: $18.39 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $244.43 | 2019-2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $192.89 | 2022-2023 | |
| Eisai INC. | $184.82 | 2022-2023 | |
| Pfizer INC. | $173.88 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $146.20 | 2019-2023 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.87 | 2022-2023 | Gilotrif |
| Astrazeneca Pharmaceuticals LP | $121.11 | 2019-2023 | Lynparza |
| Stryker Corporation | $100.69 | 2025 | Core, Nico Brainpath |
| Celgene Corporation | $70.85 | 2022-2023 | Pomalyst, Reblozyl |
| Incyte Corporation | $61.72 | 2019-2022 | |
| Daiichi Sankyo INC. | $58.13 | 2022 | |
| Gilead Sciences, INC. | $50.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.64 | 2022-2023 | Opdivo |
| Servier Pharmaceuticals LLC | $47.29 | 2022 | |
| Array Biopharma INC | $45.06 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.92 | 2022 | |
| Janssen Biotech, INC. | $33.53 | 2022 | |
| Genentech USA, INC. | $27.69 | 2023 | Rozlytrek, Alecensa, Gavreto |
| Varian Medical Systems, INC. | $24.61 | 2019 | |
| Adc Therapeutics America, INC. | $23.00 | 2023 | |
| Morphosys, US INC. | $22.52 | 2022 | |
| Aveo Pharmaceuticals, INC. | $21.88 | 2022 | |
| Genmab U.S., INC. | $21.80 | 2023 | Epkinly |
| Tesaro, INC. | $21.34 | 2019 | |
| Epizyme, INC. | $21.21 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.31 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.09 | 2022 | |
| Seagen INC. | $19.31 | 2022 | |
| Organon LLC | $19.16 | 2023 | |
| Abbvie INC. | $18.39 | 2024 | |
| Sobi, INC | $18.15 | 2023 | |
| Pharmaessentia USA Corporation | $16.83 | 2022 | |
| Puma Biotechnology, INC. | $16.65 | 2022 | |
| Eusa Pharma (US) LLC | $16.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2022 | |
| Novocure INC. | $15.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.